In this edition:
Efficacy of DMTs in people with RIS: the ARISE trial
AHSCT vs fingolimod, ocrelizumab and natalizumab in RRMS
Genetic analysis of MS severity identifies a novel locus
Rituximab vs ocrelizumab in RRMS
AHSCT vs natalizumab in progressive MS
Real-world effectiveness of DMTs
Vitamin D supplementation does not prevent RRMS in patients with high-risk CIS
Pregnancy slows progression to EDSS 4 in women with relapse-onset MS
Paramagnetic rim lesions predict the development of clinical MS in RIS patients
Precision medicine is unlikely to be the future treatment of MS
Please login below to download this issue (PDF)